GLP-1 drugs are fueling the rise of the 'big kids' market, one mega restaurant chain says

Cava CEO Brett Schulman observed that GLP-1 drugs are fueling a "big kids" market, causing adult customers to opt for smaller portions or kids' meals due to suppressed appetite and increased focus on protein. This trend is described as the "Ozempification of American food," leading packaged brands like General Mills and Conagra Brands to introduce smaller-portion products. Cava reported positive earnings, citing a 31.3% revenue increase and a 9% rise in same-store sales.